Table 2 Clinical characteristics of the audited cases
Patients (N = 4508) | Hospitals (N = 59) | p † | |||
|---|---|---|---|---|---|
N | % or median (IQR) | Median | IQR | ||
Sex (male), (%) | 4.508 | 86 | 87.5 | 82.1–93.2 | < 0.001 |
Age (years), median (P25–75) | 4.508 | 69.7 (63–77.7) | 70 | 69–72 | < 0.001 |
≤ 55 (%) | 8.5 | 8.2 | 5.8–11.7 | ||
56–69 (%) | 38.7 | 38.1 | 30–42.6 | ||
≥ 70 (%) | 52.8 | 53.3 | 47.1–61.7 | ||
Pack-years, median (P25–75) | 4.508 | 47 (34–70) | 45 | 40–51 | < 0.001 |
Active smokers, (%) | 4.508 | 23.1 | 22 | 18–29 | < 0.001 |
BMI kg/m2, median (P25–75) | 4.508 | 28.0 (24.4–31.1) | 27.8 | 26.6–28.5 | 0.03 |
≤ 21 (%) | 7.1 | 6.7 | 4.1–9.2 | ||
22–29 (%) | 60.8 | 58.8 | 56.1–64 | ||
≥ 30 (%) | 32.1 | 31.4 | 26.2–37.7 | ||
Charlson index, median (P25–75) | 4.508 | 2 (1–4) | 2 | 2–3 | < 0.001 |
≥ 3 (%) | 44.9 | 44.5 | 40–56.6 | ||
Dyspnea (MRC-m) | 4.508 | < 0.001 | |||
0 + 1 (%) | 27.3 | 23.8 | 11.6–44.5 | ||
≥ 2 (%) | 41.4 | 38.3 | 28.3–54 | ||
Missing (%) | 13.2 | 8.9 | 1.6–21.6 | ||
Level of dyspnea not referred to (%) | 18.1 | 11.6 | 3.3–30 | ||
CAT questionnaire >10, (%) | 869 | 62.4 | 64 | 47.9–83.8 | < 0.001 |
Chronic bronchitis criteria, (%) | 4.508 | 41.7 | 41 | 28.3–51 | < 0.001 |
Chronic colonization, (%) | 4.508 | 6.0 | 5 | 3.2–8.3 | < 0.001 |
Symptoms suggestive of asthma,(%) | 4.508 | 26.5 | 18.3 | 10.8–35 | < 0.001 |
% FEV1, median (P25–75) | 4.508 | 50 (37–63) | 51 | 47–54 | 0.03 |
< 50% | 49.1 | 45.5 | 41.5–53.3 | ||
50–64% | 28 | 28.5 | 22.3–31.7 | ||
≥ 65% | 22.9 | 23.8 | 15–30 | ||
Number of moderate/severe exacerbations in the last year, median (P25–75) | 3.196 | 1.1 (0–2) | 1 | 0–1 | 0.03 |
Number of hospital admissions in the last year, median (P25–75) | 4508 | 0.5 (0–1) | 0 | 0–0 | 0.03 |
BODE value, median (P25–75) | 632 | 3.9 (3–5) | 4.5 | 3–5.5 | < 0.001 |
GOLD group | 985 | < 0.001 | |||
A (%) | 22.7 | 14.3 | 0–25.9 | ||
B (%) | 18.7 | 16.7 | 0–24.1 | ||
C (%) | 18.7 | 20 | 9.8–33.3 | ||
D (%) | 39.9 | 40 | 23.5–55.6 | ||
GesEPOC Phenotype | 4.508 | < 0.001 | |||
- Non-exacerbator, (%) | 27.5 | 24.4 | 11.4–28 | ||
- Exacerbator, (%) | 18.8 | 15.7 | 3.4–22 | ||
- Missing, (%) | 53.7 | 52.3 | 44–58.9 | ||
LAMA monotherapy, (%) | 4.391 | 10.0 | 10 | 4.8–15.3 | 0.03 |
LAMA-LABA combination, (%) | 4.391 | 22.7 | 20.3 | 14.5–27.9 | < 0.001 |
LABA+ ICS combination, (%) | 4.391 | 7.7 | 6.7 | 3.4–9.8 | 0.03 |
Triple therapy (LAMA + LABA + CSI), (%) | 4.391 | 49.1 | 50.8 | 39.3–60.3 | < 0.001 |
Long-term oxygen therapy, (%) | 4.508 | 26.6% | 25 | 17.1–33.3 | 0.03 |
Home ventilation, (%) | 4.508 | 7.5% | 5 | 2.5–11.6 | < 0.001 |
Respiratory rehabilitation, (%) | 4.508 | 9 | 5 | 0–11.8 | < 0.001 |
Respiratory care follow-up (years), (%) | 4.508 | 4 (2–7) | 4 | 3.5–5 | 0.03 |